The Association for Molecular Pathology’s AMP Group released draft guidelines for interpreting and reporting cancer sequencing variants, covering biomarkers for therapy response/resistance, liquid biopsy interpretation, and mutational signatures such as TMB, MSI and HRD. The guidance aims to harmonize reporting standards across labs and improve clinical utility of tumor genomic tests. The draft clarifies when and how labs should report complex signatures and recommends standardized language for conveying clinical actionability. It also addresses practicalities around liquid biopsy result interpretation and the integration of multi‑marker results into reports. AMP seeks community feedback before finalizing the document. If adopted, these guidelines could influence lab accreditation, payer coverage decisions and clinical workflows, helping oncologists interpret NGS outputs more consistently at the point of care.